PRESS RELEASE Genkyotex’s GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis Geneva, Switzerland, and Archamps, France, 11th November, 2015 – Genkyotex, the leading de - Mechanistic target of rapamycin - Document - PDFSEARCH.IO

First Page	Meta Content
	PRESS RELEASE Genkyotex’s GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis Geneva, Switzerland, and Archamps, France, 11th November, 2015 – Genkyotex, the leading de Add to Reading List Document Date: 2015-11-12 02:47:43 Open Document File Size: 118,03 KB Share Result on Facebook

PRESS RELEASE Genkyotex’s GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis Geneva, Switzerland, and Archamps, France, 11th November, 2015 – Genkyotex, the leading deAdd to Reading List